A method of packaging a lentivirus
CN116334007BActive Publication Date: 2026-08-28LIVZON MABPHARM
Patent Information
- Application Number
- CN202310375184.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-10
- Publication Date
- 2026-08-28
- Estimated Expiration
- 2043-04-10
AI Technical Summary
Technical Problem
[0009]然而，按照上述慢病毒包装方法进行慢病毒制备时发现，上游工艺杂质过多，不满足工艺要求，显著降低了下游层析过程的载量和收率，增加了最终的产品质量不合格的风险
Benefits of technology
[0068]本领域中，包装细胞时，一般直接使用DMEM培养基或无血清培养基进行培养，而不会进行稀释，因为一般认为稀释后会使得培养基渗透压降低，不利于细胞的生存和繁殖。然而，在慢病毒的包装中，本发明的发明人在一次偶然的实验中，用稀释后的DMEM培养基或无血清培养基对转染后的细胞进行培养，意外发现，当严格控制DMEM培养基或无血清培养基的稀释倍数时，能有效降低慢病毒包装过程中的杂质，提高上游产品的质量。
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN116334007B_ABST
Abstract
The application provides a lentivirus packaging method, and the lentivirus is produced by using an adherent process or a suspension process, and the transfected cells are cultured by using diluted DMEM medium; when the dilution multiple of the DMEM medium is controlled, the impurities in the lentivirus packaging process can be effectively reduced, and the quality of the upstream product is improved. The diluted medium is matched with a specific culture temperature, so that the impurities can be further reduced, and the product quality is improved. In addition, the specific feed Cell Boost 7a or BalanCD HEK293Feed is added into the medium, so that the yield can be effectively improved.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Culture medium suitable for large-scale clinical-grade virus vector preparation and application thereof
CN113122501A
Suspension cell-based CAR-CD19 lentivirus preparation process
CN113265425A
Edia
KR1020000040714A